Dyne Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference
Dyne Therapeutics (Nasdaq: DYN), a clinical-stage neuromuscular disease company, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco. John Cox, the company's president and chief executive officer, will deliver a presentation on Wednesday, January 15, 2025, at 10:30 a.m. PT (1:30 p.m. ET).
The presentation will be accessible through a live webcast on the Investors & Media section of Dyne's website. Interested parties can view the replay for 30 days after the presentation through the company's investor relations portal at investors.dyne-tx.com.
Dyne Therapeutics focuses on developing innovative life-transforming therapeutics for individuals affected by genetically driven diseases.
Dyne Therapeutics (Nasdaq: DYN), un'azienda in fase clinica specializzata nelle malattie neuromuscolari, ha annunciato la sua partecipazione alla 43ª Conferenza Annuale J.P. Morgan Healthcare a San Francisco. John Cox, presidente e amministratore delegato dell'azienda, terrà una presentazione mercoledì 15 gennaio 2025, alle 10:30 a.m. PT (1:30 p.m. ET).
La presentazione sarà disponibile tramite un webcast in diretta nella sezione Investitori e Media del sito web di Dyne. Le parti interessate possono visualizzare la registrazione per 30 giorni dopo la presentazione attraverso il portale delle relazioni con gli investitori dell'azienda su investors.dyne-tx.com.
Dyne Therapeutics si concentra sullo sviluppo di terapie innovative che trasformano la vita per le persone affette da malattie di origine genetica.
Dyne Therapeutics (Nasdaq: DYN), una empresa en etapa clínica dedicada a las enfermedades neuromusculares, ha anunciado su participación en la 43ª Conferencia Anual J.P. Morgan Healthcare en San Francisco. John Cox, presidente y director ejecutivo de la empresa, realizará una presentación el miércoles 15 de enero de 2025, a las 10:30 a.m. PT (1:30 p.m. ET).
La presentación será accesible a través de una transmisión en vivo en la sección de Inversores y Medios del sitio web de Dyne. Las partes interesadas podrán ver la repetición durante 30 días después de la presentación a través del portal de relaciones con inversores de la empresa en investors.dyne-tx.com.
Dyne Therapeutics se centra en desarrollar terapias innovadoras que transformen la vida de las personas afectadas por enfermedades de origen genético.
Dyne Therapeutics (Nasdaq: DYN), 신경근육 질환 치료제 개발을 전문으로 하는 임상 단계 기업이 샌프란시스코에서 열리는 제43회 JP 모건 헬스케어 컨퍼런스에 참가한다고 발표했습니다. 존 콕스 회사의 사장 겸 CEO는 2025년 1월 15일 수요일 오전 10시 30분 PT(오후 1시 30분 ET)에 발표를 할 예정입니다.
발표는 Dyne의 웹사이트의 투자자 및 미디어 섹션에서 생중계로 시청할 수 있습니다. 관심 있는 분들은 발표 후 30일 동안 회사의 투자자 관계 포털인 investors.dyne-tx.com을 통해 재생 영상을 볼 수 있습니다.
Dyne Therapeutics는 유전적으로 유발된 질병으로 영향을 받는 개인을 위한 혁신적인 생명 전환 치료제 개발에 집중하고 있습니다.
Dyne Therapeutics (Nasdaq: DYN), une entreprise en phase clinique spécialisée dans les maladies neuromusculaires, a annoncé sa participation à la 43e Conférence Annuelle J.P. Morgan Healthcare à San Francisco. John Cox, le président et directeur général de l'entreprise, présentera une communication le mercredi 15 janvier 2025, à 10h30 PT (13h30 ET).
La présentation sera accessible via un webinaire en direct dans la section Investisseurs & Médias du site de Dyne. Les parties intéressées pourront visionner le replay pendant 30 jours après la présentation via le portail des relations avec les investisseurs de l'entreprise à investors.dyne-tx.com.
Dyne Therapeutics se concentre sur le développement de thérapies innovantes qui transforment la vie des personnes touchées par des maladies d'origine génétique.
Dyne Therapeutics (Nasdaq: DYN), ein Unternehmen in der klinischen Phase, das sich mit neuromuskulären Erkrankungen beschäftigt, hat seine Teilnahme an der 43. jährlichen J.P. Morgan Healthcare Conference in San Francisco angekündigt. John Cox, Präsident und Geschäftsführer des Unternehmens, wird am Mittwoch, den 15. Januar 2025, um 10:30 Uhr PT (13:30 Uhr ET) eine Präsentation halten.
Die Präsentation wird über einen Live-Stream im Bereich Investoren & Medien auf der Website von Dyne zugänglich sein. Interessierte Parteien können die Wiederholung 30 Tage nach der Präsentation über das Investor-Relations-Portal des Unternehmens unter investors.dyne-tx.com ansehen.
Dyne Therapeutics konzentriert sich auf die Entwicklung innovativer, lebensverändernder Therapeutika für Personen, die von genetisch bedingten Erkrankungen betroffen sind.
- None.
- None.
WALTHAM, Mass., Jan. 09, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage neuromuscular disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that John Cox, president and chief executive officer, is scheduled to present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 15, 2025 at 10:30 a.m. PT (1:30 p.m. ET).
A live webcast will be available in the Investors & Media section of Dyne’s website at https://investors.dyne-tx.com/news-and-events/events-and-presentations and a replay will be accessible for 30 days following the presentation.
About Dyne Therapeutics
Dyne Therapeutics is focused on discovering and advancing innovative life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Leveraging the modularity of its FORCE™ platform, Dyne is developing targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system (CNS). Dyne has a broad pipeline for neuromuscular diseases, including clinical programs for myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy (DMD) and a preclinical program for facioscapulohumeral muscular dystrophy (FSHD). For more information, please visit https://www.dyne-tx.com/, and follow us on X, LinkedIn and Facebook.
Contacts:
Investors
Mike Hencke
Kendall Investor Relations
ir@dyne-tx.com
Media
Stacy Nartker
Dyne Therapeutics
snartker@dyne-tx.com
781-317-1938
FAQ
When is Dyne Therapeutics (DYN) presenting at the 2025 J.P. Morgan Healthcare Conference?
How can investors watch Dyne Therapeutics' (DYN) J.P. Morgan Healthcare Conference presentation?
What is the focus area of Dyne Therapeutics (DYN)?
Who will represent Dyne Therapeutics (DYN) at the 2025 J.P. Morgan Healthcare Conference?
